Goodwin advised Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) on its underwritten public offering of 5,000,000 shares of its common stock at $71.87 per share, resulting in gross proceeds of $359.4 million. Alnylam intends to use the proceeds from this offering to fund clinical trial costs and other research and development expenses, continued growth of its manufacturing, quality, commercial and medical affairs capabilities to support its transition toward a commercial-stage biopharmaceutical company, and other corporate purposes.
Alnylam Pharmaceuticals, Inc. is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options.
The Goodwin team was led by partner Gregg Katz and included partner Mitchell Bloom and associate William Goldberg.
For additional details, please read the press release.